Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Blood (2024) 144 (7): 771–783.

https://doi.org/10.1182/blood.2024024299

Published: 2024

Includes: Supplemental data

Journal Articles

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Xenofon Papanikolaou, MD, Adam Rosenthal, Rashid Z Khan, MD, Joshua Epstein, DSc, Christoph Heuck, MD, Madhav V. Dhodapkar, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Omar Atiq, MD, Sarah Waheed, MD, Faith Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2079.

https://doi.org/10.1182/blood.V124.21.2079.2079

Published: 2014

Journal Articles

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Blood (2011) 118 (17): 4519–4529.

https://doi.org/10.1182/blood-2011-06-358812

Published: 2011

Journal Articles

Components of Global Quality of Life In Multiple Myeloma

Catherine D Williams, MD, Irina Proskorovsky, MSc, Philip Lewis, PhD, K. Jack Ishak, PhD, Krista A Payne, M.Ed, Noreen Lordan, BSc, Charalampia Kyriakou, MD, PhD, Faith Davies, MD, Sarah Peters, Karin Jordan, PhD

Blood (2010) 116 (21): 4735.

https://doi.org/10.1182/blood.V116.21.4735.4735

Published: 2010

Journal Articles

Determinants of Global QOL and Physical and Social Functionality In Multiple Myeloma

Karin Jordan, PhD, K. Jack Ishak, PhD, Philip Lewis, PhD, Irina Proskorovsky, MSc, Krista A Payne, M.Ed, Noreen Lordan, BSc, Charalampia Kyriakou, MD, PhD, Faith Davies, Sarah Peters, Catherine D Williams, MD

Blood (2010) 116 (21): 934.

https://doi.org/10.1182/blood.V116.21.934.934

Published: 2010

Journal Articles

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

Lauren I Aronson, Emma L Davenport, Serena G Giuntoli, Muralikrishnan Srikanth, Emma Smith, Gareth J Morgan, MD, PhD, Faith Davies

Blood (2010) 116 (21): 4083.

https://doi.org/10.1182/blood.V116.21.4083.4083

Published: 2010

Journal Articles

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Fiona M. Ross, DPhil, Laura Chiecchio, PhD, GianPaolo Dagrada, BSc, William J Tapper, PhD, Zoe J Konn, BSc, Kan Luk Cheung, BSc, Rebecca KM Protheroe, BSc, David M Stockley, BSc, Susan E Bell, DPhil, Walter M Gregory, PhD, Alexander J Szubert, MSc, Gordon Cook, MD, Roger G. Owen, MD, Mark T. Drayson, MD, Graham Jackson, DM, Faith Davies, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 2980.

https://doi.org/10.1182/blood.V116.21.2980.2980

Published: 2010

Journal Articles

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

Emma M Smith, PhD, Brian A Walker, PhD, Emma L Davenport, PhD, Lauren I Aronson, BSc.Hons., David Krige, PhD, Leon Hooftman, MD, Alan Drummond, PhD, Gareth J Morgan, MD, PhD, Faith Davies, MD

Blood (2009) 114 (22): 607.

https://doi.org/10.1182/blood.V114.22.607.607

Published: 2009

Journal Articles

Homozygous Deletions Can Be Used to Define a Cell Death Specific Gene Expression Signature Able to Predict Outcome in Myeloma

Nicholas J Dickens, DPhil, Brian Walker, PhD, Paola E Leone, PhD, Matthew W Jenner, Faith Davies, MD, Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 2725.

https://doi.org/10.1182/blood.V112.11.2725.2725

Published: 2008

Journal Articles

CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma

Stephen Schey, Gareth J Morgan, MD, PhD, Karthik Ramasamy, Beth Hazel, Karen Phekoo, Sophie Corderoy, Matthew Jenner, Faith Davies

Blood (2008) 112 (11): 3707.

https://doi.org/10.1182/blood.V112.11.3707.3707

Published: 2008

Journal Articles

Molecular Characterization of Human Multiple Myeloma Cell Lines by Genome-Wide Profiling Identifies Kinase Pathway Alterations.

Carolina Elosua, Purificacion Catalina, Brian A Walker, Nicholas J Dickens, Athanasia Avramidou, Luis Brito, Emma Davenport, PhD, Matthew W Jenner, David Gonzalez, PhD, Faith Davies, MD, Gareth J Morgan, MD, PhD, Paola E Leone, PhD

Blood (2008) 112 (11): 1694.

https://doi.org/10.1182/blood.V112.11.1694.1694

Published: 2008

Journal Articles

Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors

Emma Davenport, PhD, Athanasia Zeisig, PhD, Lauren Wiseglass, Hannah E. Moore, Sarah L. Hockley, PhD, David Gonzalez, PhD, Emma Smith, PhD, Swee Sharp, PhD, Paul Workman, PhD, Gareth J Morgan, MD.PhD., Faith Davies, MD

Blood (2008) 112 (11): 2625.

https://doi.org/10.1182/blood.V112.11.2625.2625

Published: 2008

Journal Articles

An Early CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective Strategy with Low Mortality.

Fiona L Dignan, Stephen O Evans, Mark E Ethell, Bronwen E. Shaw, Unell BG Riley, Faith Davies, Jennifer G. Treleaven, Claire E. Dearden, Gareth J. Morgan, Michael N Potter

Blood (2008) 112 (11): 1149.

https://doi.org/10.1182/blood.V112.11.1149.1149

Published: 2008

Journal Articles

siRNA Knockdown of MMSET Disrupts Cell Cycle and Induces Apoptosis in t(4;14) Myeloma.

Jose Brito, Brian Walker, Faith Davies, Julie Irving, Gareth J. Morgan

Blood (2007) 110 (11): 245.

https://doi.org/10.1182/blood.V110.11.245.245

Published: 2007

Journal Articles

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

Faith Davies, MD, Gert Ossenkoppele, MD, Pierre Zachee, MD, Richard Noppeney, MD, Alan Burnett, MD, Michel Delforge, MD, Pieter Sonneveld, MD, Gareth Morgan, MD, Sonja Zweegman, MD, Dimitri Breems, MD, Alison Richardson, PhD, Leon Hooftman, MD, Bob Lowenberg, MD

Blood (2007) 110 (11): 443.

https://doi.org/10.1182/blood.V110.11.443.443

Published: 2007

Journal Articles

Inherited Genetic Variation and the Risk of Developing Venous Thrombosis with Thalidomide Treatment in Myeloma Patients.

David C. Johnson, BSc, Suzanne Grindle, BS, Faith Davies, MD, David Gonzalez, PhD, Christine Ramos, PhD, Kim Hawkins, MSc, Suzanne Bell, PhD, Heather Kesby, BSc, S. Vincent Rajkumar, MD, Erik Rassmusen, PhD, John Crowley, PhD, Emily Blood, PhD, J. Anthony Child, MD, Brian G.M. Durie, MD, Brian G. Van Ness, PhD, Gareth J. Morgan, MDPhD

Blood (2005) 106 (11): 1624.

https://doi.org/10.1182/blood.V106.11.1624.1624

Published: 2005

Journal Articles

Development of a Panel of 3,500 SNP Based Functional Genetic Variants Relevant to the Etiology and Outcome in Multiple Myeloma.

David C. Johnson, BSc, Suzanne M. Grindle, BS, Christine Ramos, PhD, Faith Davies, MD, David Gonzalez, PhD, Brian A. Walker, PhD, Brian G.M. Durie, MD, Brian G. Van Ness, Phd, Gareth J. Morgan, MD, PhD

Blood (2005) 106 (11): 620.

https://doi.org/10.1182/blood.V106.11.620.620

Published: 2005

Journal Articles

Identification of genes modulated in multiple myeloma using genetically identical twin samples

Nikhil C. Munshi, Teru Hideshima, Daniel Carrasco, Masood Shammas, Daniel Auclair, Faith Davies, Nicholas Mitsiades, Constantine Mitsiades, Ryung Suk Kim, Cheng Li, S. Vincent Rajkumar, Rafael Fonseca, Lief Bergsagel, Dharminder Chauhan, Kenneth C. Anderson

Blood (2004) 103 (5): 1799–1806.

https://doi.org/10.1182/blood-2003-02-0402

Published: 2004

Journal Articles

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Blood (2002) 100 (9): 3063–3067.

https://doi.org/10.1182/blood-2002-03-0996

Published: 2002

Journal Articles

Absence of biologically important Kaposi sarcoma–associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma

Christian Brander, Noopur Raje, Paula G. O'Connor, Faith Davies, Jennifer Davis, Darminder Chauhan, Teru Hideshima, Jeff Martin, Dennis Osmond, Dean H. Kedes, Bruce D. Walker, David T. Scadden, Kenneth C. Anderson

Blood (2002) 100 (2): 698–700.

https://doi.org/10.1182/blood.V100.2.698

Published: 2002

NARROW

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Components of Global Quality of Life In Multiple Myeloma

Determinants of Global QOL and Physical and Social Functionality In Multiple Myeloma

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.

Homozygous Deletions Can Be Used to Define a Cell Death Specific Gene Expression Signature Able to Predict Outcome in Myeloma

CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma

Molecular Characterization of Human Multiple Myeloma Cell Lines by Genome-Wide Profiling Identifies Kinase Pathway Alterations.

Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors

An Early CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective Strategy with Low Mortality.

siRNA Knockdown of MMSET Disrupts Cell Cycle and Induces Apoptosis in t(4;14) Myeloma.

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

Inherited Genetic Variation and the Risk of Developing Venous Thrombosis with Thalidomide Treatment in Myeloma Patients.

Development of a Panel of 3,500 SNP Based Functional Genetic Variants Relevant to the Etiology and Outcome in Multiple Myeloma.

Identification of genes modulated in multiple myeloma using genetically identical twin samples

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Absence of biologically important Kaposi sarcoma–associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only